Selank for Laboratory Research

Selank is a synthetic linear heptapeptide and a tuftsin analogue. Its sequence contains seven residues in a defined order, combining the tuftsin fragment Thr-Lys-Pro-Arg with the C-terminal extension Pro-Gly-Pro. Scientific publications also refer to the substance by the development code TP-7.

The identifiers below refer to the free peptide form represented by PubChem. They provide reconciliation points for a reference structure, but none alone authenticates supplied material.

These registry identifiers apply to the free peptide form. A salt form may alter the formula and molecular mass, so the documented chemical form must be reconciled with the label, released specification and applicable batch COA. Database identity and batch identity remain separate information layers.

Structural context: Siebert et al., 2017 review

Tuftsin is the tetrapeptide Thr-Lys-Pro-Arg. Selank contains this full motif and adds Pro-Gly-Pro at the C-terminus. “Tuftsin analogue” therefore describes structural derivation; it does not make the two substances analytically or experimentally interchangeable.

Siebert et al. reviewed chemical variants and heterogeneous experimental fields involving tuftsin derivatives. As a review, it provides context across sources; the relevant primary publication must still be consulted for any specific scientific statement.

Tuftsin lineage: Siebert et al., 2017 — Review

No established receptor accounts for every published Selank observation. The research separates several measurement levels: GABA-related transcripts, BDNF-related measurements, immune-related gene expression and a supplementary enzyme measurement in human plasma. These levels are not interchangeable.

Volkova et al. reported time-dependent differences in selected GABA-related transcripts in the frontal cortex in a preclinical rat model. Filatova et al. used an in-vitro human neuroblastoma cell line and found that Selank alone did not alter the mRNA levels examined in that system; combined conditions produced different expression patterns. The single-substance null result prevents a uniform mechanism claim across these experimental systems.

Inozemtseva et al. measured time-dependent BDNF mRNA changes in the hippocampus in vivo in a preclinical rat model. Kolik et al. examined BDNF content in the hippocampus and prefrontal cortex in a preclinical rat model involving prolonged ethanol exposure. Kolomin et al. analysed a panel of 84 inflammation-related genes in mouse spleen at two time points in a preclinical mouse model and also examined peptide fragments.

mRNA is neither evidence of binding nor a measure of protein abundance. Tissue, model, method, comparison and measurement time remain part of each finding, and none of these molecular endpoints establishes properties of supplied material.

Endpoint records: Volkova et al., 2016 · Filatova et al., 2017 · Inozemtseva et al., 2008 · Kolik et al., 2019 · Kolomin et al., 2011

This section describes findings in controlled research and makes no statement about use. The rows are ordered by model type, from in vitro through preclinical animal models to review and clinical investigation. That order is organisational, not an evidential hierarchy, and every finding remains bounded by its stated model and endpoint.

The human cell line is not a study with participants. Zozulya et al., by contrast, is a clinical investigation with human participants and a supplementary enzyme measurement in human plasma. This page does not transfer findings from studies with human participants to the offered laboratory material.

Evidence map: seven model-qualified records linked in the timeline above.

Selank contains the full tuftsin motif Thr-Lys-Pro-Arg and extends it with Pro-Gly-Pro. Tuftsin and Selank therefore have different sequences, and their measurements cannot be treated as equivalent.

Selank and Semax are distinct research peptides, each with its own sequence, literature and batch documentation. This is an identity distinction only, not a comparison, ranking or recommendation.

N-acetyl Selank is a form variant listed in the market and requires its own identity verification. It must not be substituted for the sequence documented here on the basis of naming similarity. TP-7 is also referred to as the development code for Selank, but the code alone is not evidence of identity. The phrase Selank TP-7 does not replace sequence and batch-document reconciliation.

Nomenclature context: Siebert et al., 2017 — Review

For laboratories that buy Selank as reference material for a documented research project, Reborn Peptides SRL lists the material in lyophilised form with a declared content of 10 mg. Lyophilisation describes the freeze-dried state; it is not evidence of identity or purity. The declared content is catalogue information and must remain distinct from analytical findings.

The applicable COA must be attributable to the supplied batch through the product name and batch code. The compound name, declared content, test date, analytical method and reported result should be reconciled. An HPLC value can document chromatographically determined purity only for the tested batch and is not a blanket purity statement or an automatic substitute for an independent identity test.

The documented salt form remains part of this reconciliation because the PubChem identifiers describe the free peptide form. Binding storage information comes from the label, released specification and applicable batch COA; no temperature, stability period or shelf-life is stated here. Literature records, database identifiers and supply documentation answer different questions and cannot substitute for one another.

Research use only. For laboratory research only. Not intended for humans or animals. Not a medicinal product, food or cosmetic. This product is not intended to diagnose, treat, cure or prevent any disease.